Natural Products Derived from Fungi and Their Biological Activities, 2nd Edition

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: 25 December 2025 | Viewed by 1049

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmaceutical Botany, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
Interests: medicinal mushrooms; mycelial cultures; biotechnology; bioactive compounds; pro-health activity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Medicinal fungi are products that have been present in human life for centuries. On the one hand, mushrooms were appreciated for their flavor, aroma, and nutritional potential; on the other hand, they were a source of bioactive substances and were used as medicines. In recent years, due to the development of analytical techniques, more and more fungi properties are being recognized, and their specific mechanisms of action are being determined. It has been proven that fungi exhibit a number of activities, including antioxidant, immunostimulant, antimicrobial, anti-atherosclerotic, and anti-inflammatory effects. Despite the numerous reports on fungi, there is a constant need for new work on a broad and comprehensive analysis of such natural products, so that they can be used in the prevention and treatment of diseases.

This Special Issue covers any topic related to medicinal fungi, welcoming brief reports, communications, research articles, and reviews.

Dr. Katarzyna J. Kała
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • fungi
  • medicinal fungi
  • fruiting bodies
  • mycelial cultures
  • bioactive compounds
  • pro-health activity
  • mushroom products
  • natural therapy
  • natural medicines

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Other

3 pages, 154 KB  
Editorial
Advances in Fungal Natural Products: Insights into Bioactivity and Therapeutic Potential
by Katarzyna Kała
Pharmaceuticals 2025, 18(9), 1313; https://doi.org/10.3390/ph18091313 - 1 Sep 2025
Viewed by 745
Abstract
Medicinal fungi represent a unique and underexploited reservoir of structurally diverse natural products with profound biological activities [...] Full article

Other

Jump to: Editorial

35 pages, 5100 KB  
Systematic Review
Can Ganoderma Triterpenoids Exert Immunogenic Cell Death in Human Cancer Cells? A Systematic Review and Protein Network Analysis
by Jorge C. Ramírez-Gutiérrez, J. Fernando Ayala-Zavala, Heriberto Torres-Moreno, Max Vidal-Gutiérrez and Martín Esqueda
Pharmaceuticals 2025, 18(11), 1641; https://doi.org/10.3390/ph18111641 - 30 Oct 2025
Viewed by 116
Abstract
Background: Permanent cancer resolution requires a complete immunological response with generation of memory against malignant cells. Immunogenic cell death (ICD) achieves this by coupling cell death with the emission of damage-associated molecular patterns (DAMPs). Current cancer treatments immunosuppress the host; thus, new [...] Read more.
Background: Permanent cancer resolution requires a complete immunological response with generation of memory against malignant cells. Immunogenic cell death (ICD) achieves this by coupling cell death with the emission of damage-associated molecular patterns (DAMPs). Current cancer treatments immunosuppress the host; thus, new alternatives are needed. Ganoderma species produce anticancer triterpenoids (GTs); however, their mechanism remains unclear. Objective: This systematic review aims to provide insights into GTs’ pharmacodynamics and assess hypothetical ICD potential. Methods: Web of Science and PubMed databases were consulted following PRISMA guidelines. Studies from inception until 2024, reporting molecular changes associated with GTs’ anticancer effects, were considered. Nonhuman models were excluded. GTs and GTs-ICD converging molecular targets were listed and submitted to Cytoscape’s stringApp to construct protein interaction networks. Topological and enrichment analysis were performed. Results: A total of 204 articles were found, and 69 remained after screening. Overall anticancer effects include loss of mitochondrial membrane potential, DNA and RNA damage, autophagy, cell cycle arrest, and leukocyte activation. 136 molecular targets of GTs were identified; upregulated proteins include CHOP, PERK, p-eIF2α, and HSP70, a key DAMP. GTs and ICD share 24 molecular targets. GO:BP and KEGG enrichment analysis suggest that GTs’ anticancer effects are related to stress response, cell death regulation, and PD-L1/PD-1 checkpoint inhibition. GT-ICD enrichment converges on endoplasmic reticulum stress, unfolded protein response, and organelle membrane perforation. Conclusions: GTs exhibit polypharmacological anticancer effects, including anti-immunosuppression, upregulation of ICD-adjacent machinery, and even an increase in HSP. However, further studies are required to confirm a proper causal link between GTs’ cancer cell treatment and DAMP emission. Full article
Show Figures

Graphical abstract

Back to TopTop